Synergistic effect of a novel focal hyperthermia on the efficacy of rifampin in staphylococcal experimental foreign-body infection

Journal of International Medical Research

Volumn 37, Issue 4, 2009, Pages 1115-1126

  Zou, G Y ^a   Shen, H ^a   Jiang, Yao ^a   Zhang, X L ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Antibiotics; Focal hyperthermia; Foreign body infection; Methycillin resistant staphylococcus aureus; Rifampin

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; EXPERIMENTAL RABBIT; FOREIGN BODY; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOFILM; DIFFUSION CHAMBER; DISEASE MODEL; DRUG EFFECT; FOREIGN BODY GRANULOMA; HYPERTHERMIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; PENICILLIN RESISTANCE; RABBIT; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BIOFILMS; COLONY COUNT, MICROBIAL; DIFFUSION CHAMBERS, CULTURE; DISEASE MODELS, ANIMAL; GRANULOMA, FOREIGN-BODY; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; MALE; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RABBITS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 70350490518     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700416     Document Type: Article

References (39)

1. Darouiche RO: Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001; 33: 1567-1572.
2. Zimmerli W, Waldvogel FA, Vaudaux P, et al: Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982; 146: 487-497.
3. Zimmerli W: Prosthetic joint infection: diagnosis and treatment. Curr Infect Dis Rep 2000; 2: 377-379.
4. Anguita-Alonso P, Hanssen AD, Patel R: Prosthetic joint infection. Expert Rev Anti Infect Ther 2005; 3: 797-804.
5. Trampuz A, Widmer AF: Infections associated with orthopedic implants. Curr Opin Infect Dis 2006; 19: 349-356.
6. Widmer AF: New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001; 33(suppl 2): S94-S106. (Pubitemid 32762927)
7. Zimmerli W, Trampuz A, Ochsner PE: Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-1654.
8. Brandt CM, Duffy MC, Berbari EF, et al: Staphylococcus aureus prosthetic joint infection treated with prosthesis removal and delayed reimplantation arthroplasty. Mayo Clin Proc 1999; 74: 553-558.
9. Donlan RM: Biofilms and device-associated infections. Emerg Infect Dis 2001; 7: 277-281.
10. Drancourt M, Stein A, Argenson JN, et al: Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-240. (Pubitemid 27116419)
11. Zimmerli W, Widmer AF, Blatter M, et al for the Foreign-Body Infection (FBI) Study Group: role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 1998; 279: 1537-1541.
12. Widmer AF, Wiestner A, Frei R, et al: Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991; 35: 741-746.
13. Zavasky DM, Sande MA: Reconsideration of rifampin: a unique drug for a unique infection. JAMA 1998; 279: 1575-1577.
14. Widmer AF, Frei R, Rajacic Z, et al: Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990; 162: 96-102. (Pubitemid 20223955)
15. Zimmerli W, Frei R, Widmer AF, et al: Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 959-967. (Pubitemid 24170895)
16. Soriano A, Garcia S, Bori G, et al: Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbiol Infect 2006; 12: 930-933. (Pubitemid 44151298)
17. Widmer AF, Gaechter A, Ochsner PE, et al: Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992; 14: 1251-1253.
18. Murillo O, Domenech A, Garcia A, et al: Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 4011-4017. (Pubitemid 44865143)
19. Thomson CJ: The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother 1999; 43(suppl A): 31-40.
20. Bonomo RA: Multiple antibiotic-resistant bacteria in long-term-care facilities: an emerging problem in the practice of infectious diseases. Clin Infect Dis 2000; 31: 1414-1422.
21. Shams WE, Rapp RP: Methicillin-resistant staphylococcal infections: an important consideration for orthopedic surgeons. Orthopedics 2004; 27: 565-568.
22. Tverdek FP, Crank CW, Segreti J: Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin 2008; 24: 249-260.
23. Song CW, Park H, Griffin RJ: Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 2001; 155: 515-528. (Pubitemid 32260249)
24. Di Cesare GA, Pacetti P, Ichinoseki-Sekinek N, et al: Hyperthermia induced by microwave diathermy in the management of muscle and tendon injuries. Br Med Bull 2007; 83: 379-396. (Pubitemid 47614261)
25. Bennett IL, Nicastri A: Fever as a mechanism of resistance. Bacteriol Rev 1960; 24: 16-34.
26. Jiang Q, Cross AS, Singh IS, et al: Febrile core temperature is essential for optimal host defense in bacterial peritonitis. Infect Immun 2000; 68: 1265-1270. (Pubitemid 30108520)
27. Roberts NJ: Temperature and host defense. Microbiol Rev 1979; 43: 241-259.
28. Weinstein MP, Iannini PB, Stratton CW, et al: Spontaneous bacterial peritonitis. A review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med 1978; 64: 592-598.
29. Sande MA, Sande ER, Woolwine JD, et al: The influence of fever on the development of experimental Streptococcus pneumoniae meningitis. J Infect Dis 1987; 156: 849-850.
30. Small PM, Tauber MG, Hackbarth CJ, et al: Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect Immun 1986; 52: 484-487.
31. Lucet JC, Herrmann M, Rohner P, et al: Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34: 2312-2317.
32. Chuard C, Herrmann M, Vaudaux P, et al: Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991; 35: 2611-2616.
33. Schaad HJ, Chuard C, Vaudaux P, et al: Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin-susceptible and-resistant Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 1191-1200. (Pubitemid 24201962)
34. Vaudaux P, Francois P, Bisognano C, et al: Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 1503-1509. (Pubitemid 34415334)
35. Chuard C, Lucet JC, Rohner P, et al: Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 1991; 163: 1369-1373.
36. Murray PR Baron EJ, Jorgenson JH, et al: Manual of Clinical Microbiology 8th edn. Washington: American Society for Microbiology Press, 2003; pp 210-211.
37. Blaser J, Vergeres P, Widmer AF, et al: In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother 1995; 39: 1134-1139.
38. Honess DJ, Donaldson J, Workman P, et al: The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. Br J Cancer 1985; 51: 77-84. (Pubitemid 15151691)
39. Skibba JL, Jones FE, Condon RE: Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. Cancer Treat Rep 1982; 66: 1357-1363.